It has recently been shown that up to 75% of all breast cancer patients bear antibodies against at least one of the following antigens: p53, c-myc, NY-ESO-1, BRCA1, BRCA2, HER2, or MUC1. This evidence concerns the gene TP53 and breast carcinoma.